Abstract:Abstract Developing emergency drugs in time is key to responding to public health emergencies such as the coronavirus disease 2019 (COVID-19) pandemic. This research constructs patent assignee citation networks based on COVID-19 drug patents and applies technology life cycle analysis and social network analysis to examine these networks. The results reveal the evolution and structure of the emergency drug innovation network and identify innovation entities with different research and development (R&D) capabilities or a foundation for cooperation. This study attempts to provide the basis for theories and policies to accelerate R&D of emergency drugs. The key results are as follows: (1) Technologies of the emergency drug innovation network show fluctuating growth aligned closely with public health emergencies. (2) The network presents a sparse structure with many active factions, whose members have the advantage of cooperating. (3) Three types of innovation entities are identified: the main technology suppliers, potential suppliers of other supporting technologies, and peripheral suppliers of other supporting technologies.

Evolution of the emergency drug innovation network and policy implications: Evidence from COVID-19 drug patents